ADPS™
PIK3CA Mutation Test Kit
Ultra-Sensitivity Enhancing PIK3CA Research Outcomes
Ultra-Sensitivity Enhancing PIK3CA Research Outcomes
The PIK3CA gene encodes the alpha isoform protein (p110α) of phosphatidylinositol 3-kinase (PI3K), which is involved in cell signaling. Mutations in the PIK3CA gene cause excessive activation of downstream signaling pathways, leading to abnormalities in cell growth/division, protein translation/synthesis, and programmed cell death.
In breast cancer, PIK3CA is associated with resistance to hormone therapy and disease progression. PIK3CA gene mutations are observed in various cancer types, including colorectal, endometrial, lung, and breast cancer. About 70% of breast cancer patients are hormone receptor-positive (HR+), HER2 gene mutation-negative (-), and about 40% of these have PIK3CA gene mutations. PIK3CA mutation information can help guide the consideration of prescribing PIQRAY for breast cancer treatment.
The ADPS™ PIK3CA Mutation Test Kit detects 11 mutations in exons 7, 9, and 20 of the PIK3CA gene with a high sensitivity of up to 0.03%. It is designed for testing both tissue and plasma samples with a single kit.
This product is for research use only (RUO) and not intended for use in diagnostic procedures
| Catalog No. | (RUO) R8003APA |
|---|---|
| Detection target | 11 mutations in PIK3CA exon 7, 9 and 20 |
| Assay type | qPCR |
| Sample type | DNA extracted from FFPE, frozen, and fresh cancer tissue or liquid biopsy |
| Master Mixture (MMX) |
4MMXs |
| Internal Control | PIK3CA exon 16 |
| Detection Sensitivity | 0.03-0.5% |
| Detection Specificity | ≥ 99.0% |
| Precision (% CV) | ≤ 5% (CV, coefficient of variation) |
| Storage | -20±5℃ |
| Stability | 18 months |
| Freeze/Thaw stability | 5 times |
| Compatible Instruments | AB 7500 Fast, CFX96, QuantStudio5 |
ADPS™ Oncogene Mutation Test